Compare ESQ & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | ABUS |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 839.5M |
| IPO Year | 2017 | 2008 |
| Metric | ESQ | ABUS |
|---|---|---|
| Price | $113.60 | $4.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $120.33 | $5.00 |
| AVG Volume (30 Days) | 91.1K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | 14.20 | ★ 55.26 |
| EPS | ★ 1.40 | 0.87 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $35.15 | N/A |
| Revenue Next Year | $39.09 | $239.71 |
| P/E Ratio | $80.15 | ★ $5.07 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $88.47 | $3.04 |
| 52 Week High | $119.86 | $5.10 |
| Indicator | ESQ | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 62.39 |
| Support Level | $104.40 | $4.15 |
| Resistance Level | $118.39 | $4.86 |
| Average True Range (ATR) | 3.29 | 0.16 |
| MACD | 0.35 | 0.03 |
| Stochastic Oscillator | 59.11 | 99.15 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.